FOLLICULAR LYMPHOMA (FL)

This early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This phase 3 trial tests an experimental drug called odronextamab for people with previously untreated follicular lymphoma, a slow-growing blood cancer. The study compares odronextamab alone or with standard chemotherapy to see if it leads to better remission rates. About 822 par…

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This early-phase study tests a new drug called NX-5948 in adults with advanced B-cell blood cancers (like certain leukemias and lymphomas) that have not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The main goa…

This early-phase trial is testing a new cell therapy called GF-CART01 for people with certain B-cell blood cancers (like lymphoma) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two cancer markers (CD…

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…

This study tests whether adding the investigational drug epcoritamab to standard therapy (rituximab and lenalidomide) works better than standard chemoimmunotherapy for people with untreated follicular lymphoma, a slow-growing blood cancer. About 1,095 adults will be randomly assi…

This study tests an experimental drug called MDX2003 in 180 adults with B-cell lymphomas (like diffuse large B-cell lymphoma or follicular lymphoma) that have returned or stopped responding to at least two prior treatments. The main goals are to find the safest dose and check if …

This early-phase study tests a new treatment called CT1182 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. About 24 participants will receive the treatment to see if it is safe and how well it works. The goal is to find the bes…

This study tests a personalized cell therapy called Talikabtagene Autoleucel for people with B-cell leukemia or lymphoma that has returned or not responded to standard treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack ca…

This early-stage trial tests a new oral drug called NX-2127 in adults with advanced B-cell cancers (like certain leukemias and lymphomas) that have not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The main goals are to …

This early-phase trial tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …

This phase 2 trial is testing a combination of two drugs—a CAR-T cell therapy (relmacabtagene autoleucel) and a PD-1 inhibitor (sintilimab)—in 30 adults with relapsed or refractory B-cell lymphoma. The goal is to see if the combo can shrink tumors and improve survival. Participan…

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…

This study is a large registry that will follow nearly 3,000 people with blood cancers like chronic lymphocytic leukemia and several types of lymphoma. Researchers will collect information on treatments, how the disease progresses, and patients' quality of life over time. The goa…